Latent agonist activity of the steroid antagonist, RU486, is unmasked in cells treated with activators of protein kinase A

Molecular Endocrinology

Volumn 7, Issue 6, 1993, Pages 731-742

  Nordeen, Steven K ^a   Bona, Betty J ^a   Moyer, Marissa L ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 BROMO CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DEXAMETHASONE; ENZYME ACTIVATOR; FORSKOLIN; GLUCOCORTICOID RECEPTOR; MIFEPRISTONE; ONAPRISTONE; PROGESTERONE RECEPTOR;

ANIMAL CELL; ARTICLE; CANCER RESEARCH; CELL LINE; CONTROLLED STUDY; DNA BINDING; DRUG MECHANISM; ENZYME ACTIVATION; FIBROBLAST; GENE INDUCTION; HORMONE RESPONSIVE ELEMENT; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; SIGNAL TRANSDUCTION;

8-BROMO CYCLIC ADENOSINE MONOPHOSPHATE; BLOTTING, WESTERN; CELL LINE; DEXAMETHASONE; ENZYME ACTIVATION; FIBROBLASTS; FORSKOLIN; GENE EXPRESSION; MAMMARY TUMOR VIRUS, MOUSE; MIFEPRISTONE; PROMOTER REGIONS (GENETICS); PROTEIN KINASE C; PROTEIN KINASES; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION; SUPPORT, U.S. GOV'T, P.H.S.;

ANIMALIA; MAMMARY TUMOR ONCOVIRUS; MAMMARY TUMOR VIRUS; MOUSE MAMMARY TUMOR VIRUS; ONCOVIRINAE; TUMOR VIRUS;

EID: 0027220012     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/mend.7.6.8395651     Document Type: Article

References (52)

1. Philibert D 1984 RU 38486: An original multifaceted antihormone in vivo. In: Agarwal MK (ed) Adrenal Steroid Antagonism. Walter de Gruyter & Co., New York, pp 77101
2. Ulmann A, Teutsch G, Philibert D 1990 RU486. Scl Am 262: 42-48
3. Mao J, Regelson W, Kalimi M 1992 Molecular mechanism of RU486 action: A review. Mol Cell Blochem 109: 1-8
4. Horwitz KB 1992 The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer? Endocr Rev 13: 146-163
5. Baulleu E-E 1989 Contragestion and other clinical applications for RU486, an antiprogesterone at the receptor. Science 245: 1351-1357
6. Kettel LM, Murphy AA, Mortola JF, Liu JH, Ulmann A, Yen SSC 1991 Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis. Fertil Steril 56: 402-407
7. Lamberts SWJ, Tanghe HU, Avezaat CJJ, Braakman R, Wijngaarde R, Koper JW, De Jong FH 1992 Mifepristone (RU486) treatment of meningiomas. J Neurol Neurosurg Psychiatry 55: 486-490
8. Bakker GH, Setyono-Han B, Portengen H, De Jong FH, Foekens JA, Klijn JGM 1990 Treatment of breast cancer with different antiprogestins: Preclinical and clinical studies. J Steroid Biochem Mol Biol 37: 789-794
9. Maudelonde T, Romieu G, Ulmann A, Pujol H, Grenier J, Khalaf S, Cavalie G, Rochefort H 1987 First clinical trial on the use of the antiprogestin RU486 in advanced breast cancer. In: Klijn JGM, Paridaens R, Foekens JA (eds) Hormonal Manipulation of Cancer: Peptides, Growth Factors and New (Anti-) Steroidal Agents. Raven Press, New York, pp 55-59
10. Klijn JGM, De Jong FH, Bakker GH, Lamberts SWJ, Rodenburg CJ, Alexieva-Figusch J 1989 Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res 49: 2851-2856
11. Moguilewsky M, Philibert D 1984 RU 38486: Potent anti-glucocorticoid activity correlated with strong binding to the cytosolic glucocorticoid receptor followed by an impaired activation. J Steroid Biochem 20: 271-276
12. Distelhorst CW, Howard KJ 1990 Evidence from pulse-chase labeling studies that the antiglucocorticoid hormone RU486 stabilizes the nonactivated form of the glucocorticoid receptor in mouse lymphoma cells. J Steroid Biochem Mol Biol 36: 25-31
13. Guiochon-Mantel AG, Loosfelt H, Ragot T, Bailly A, Atger M, Mlsrahi M, Perricaudet M, Milgrom E 1988 Receptors bound to antiprogestin form abortive complexes with hormone responsive elements. Nature 336: 695-698
14. El Ashry D, Oriate SA, Nordeen SK, Edwards DP 1989 Human progesterone receptor complexed with the antagonist RU486 binds to hormone response elements in a structurally altered form. Mol Endocrinol 3: 1545-1558
15. Meyer M-E, Pornon A, Ji J, Bocquel M-T, Chambon P, Gronemeyer H 1990 Agonistic and antagonistic activities of RU486 on the functions of the human progesterone receptor. EMBO J 9: 3923-3932
16. Klein-Hitpass L, Cato ACB, Henderson D, Ryffel GU 1991 Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells. Nucleic Acids Res 19: 1227-1234
17. Nath R, Bhakta A, Moudgil VK 1992 ZK98 299 a new antiprogesterone: Biochemical characterization of steroid binding parameters in the calf uterine cytosol. Arch Biochem Biophys 292: 303-310
18. DeMarzo AM, Oriate SA, Nordeen SK, Edwards DP 1992 Effects of the steroid antagonist RU486 on dimerization of the human progesterone receptor. Biochemistry 31: 10491-10501
19. Beck CA, Estes PA, Bona BJ, Muro-Cacho CA, Nordeen SK, Edwards DP, The steroid antagonist RU486 exerts different effects on the glucocorticoid and progesterone receptors. Endocrinology, in press
20. Mullick A, Katzenellenbogen BS 1986 Antiprogestin-receptor complexes: Differences in the interaction of the antiprogestin RU38.486 and the progestin R 5020 with the progesterone receptor of human breast cancer cells. Biochem Biophys Res Commun 135: 90-97
21. Weigel NL, Beck CA, Estes PA, Prendergast P, Altmann M, Christensen K, Edwards DP 1992 Ligands induce conformational changes in the carboxyl-terminus of progesterone receptors which are detected by a site-directed antipeptide monoclonal antibody. Mol Endocrinol 6: 1585-1597
22. Allan GF, Leng X, Tsai SY, Weigel NL, Edwards DP, Tsai M-J, O’Malley BW 1992 Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. J Biol Chem 267: 19513-19520
23. Vegeto E, Allan GF, Schrader WT, Tsai M-J, McDonnell DP, O’Malley BW 1992 The mechanism of RU486 antagonism is dependent on the conformation of the carboxyterminal tail of the human progesterone receptor. Cell 69: 703-713
24. Nordeen SK, Moyer ML, Bona BJ 1992 Cell Signalling and the modulation of glucocorticoid receptor activity. J Cell Biochem [Suppl] 16: 21
25. Chandler VL, Maler BA, Yamamoto KR 1983 DNA sequences bound specifically by glucocorticoid receptor in vitro render a heterologous promoter hormone responsive in vivo. Cell 33: 489-499
26. Majors J, Varmus HE 1983 A small region of the mouse mammary tumor virus long terminal repeat confers glucocorticoid hormone regulation on a linked heterologous gene. Proc Natl Acad Scl USA 80: 5866-5870
27. Buetti E, Diggelmann H 1983 Glucocorticoid regulation of mouse mammary tumor virus: Identification of a short essential DNA region. EMBO J 2: 1423-1429
28. Ponta H, Kennedy N, Skroch P, Hynes NE, Groner B 1985 Hormonal response region in the mouse mammary tumor virus long terminal repeat can be dissociated from the proviral promoter and has enhancer properties. Proc Natl Acad Sci USA 82: 1020-1024
29. Nowock J, Borgmeyer U, Puschel AW, Rupp RAW, Sippel AE 1985 The TGGCA protein binds to the MMTV-LTR, the adenovirus origin of replication, and the BK virus enhancer. Nucleic Acids Res 13: 2045-2061
30. Cordingley MG, Riegel AT, Hager GL 1987 Steroid-dependent interaction of transcription factors with the inducible promoter of mouse mammary tumor virus in vivo. Cell 48: 261-270
31. Buetti E, Kuhnel B, Diggelmann H 1989 Dual function of a nuclear factor I binding site in MMTV transcription regulation. Nucleic Acids Res 17: 3065-3078
32. Toohey MG, Lee JW, Huang M, Peterson DO 1990 Functional elements of the steroid hormone-responsive promoter of mouse mammary tumor virus. J Virol 64: 4477-4488
33. Meulia T, Diggelmann H 1990 Tissue-specific factors and glucocorticoid receptors present in nuclear extracts bind next to each other in the promoter region of mouse mammary tumor virus. J Mol Biol 216: 859-872
34. Briiggemeier U, Kalff M, Franke S, Scheidereit C, Beato M 1991 Ubiquitous transcription factor OTF-1 mediates induction of the MMTV promoter through synergistic interaction with hormone receptors. Cell 64: 565-572
35. Gunzburg WH, Salmons B 1992 Factors controlling the expression of mouse mammary tumour virus. Biochem J 283: 625-632
36. Beck CA, Weigel NL, Moyer ML, Nordeen SK, Edwards DP, The progesterone antagonist RU486 acquires agonist activity upon stimulation of signal transduction pathways by 8-Br cAMP. Proc Natl Acad Sci USA, in press
37. Nordeen SK, Kuhnel B, Lawler-Heavner J, Barber DA, Edwards DP 1989 A quantitative comparison of dual control of a hormone response element by progestins and glucocorticoids in the same cell line. Mol Endocrinol 3: 1270-1278
38. Bastian LS, Nordeen SK 1991 Concerted stimulation of transcription by glucocorticoid receptors and basal transcription factors, limited synergism suggests mediation by coactivators/adaptors. Mol Endocrinol 5: 619-627
39. Choi Y, Kappler JW, Marrack P 1991 A superantigen encoded in the open reading frame of the 3' long terminal repeat of mouse mammary tumour virus. Nature 350: 203-207
40. Acha-Orbea H, Shakhov AN, Scarpellino L, Kolb E, Muller V, Vessaz-Shaw A, Fuchs R, Blochlinger K, Rollini P, Billotte J, Sarafidou M, MacDonald HR, Diggelmann H 1991 Clonal deletion of V14-bearing T cells in mice transgenic for mammary tumour virus. Nature 350: 207-211
41. Gruol DJ, Altschmied J 1993 Synergistic induction of apoptosis with glucocorticoids and 3',5'-cyclic adenosine monophosphate reveals agonist activity by RU486. Mol Endocrinol 7: 104-113
42. Sartorius CA, Tung L, Takimoto GS, Horwitz KB, Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP. J Biol Chem, in press
43. Oshima H, Simons Jr SS 1992 Modulation of transcription factor activity by a distant steroid modulatory element. Mol Endocrinol 6: 416-428
44. Gametchu B, Harrison R 1984 Characterization of a monoclonal antibody to the rat liver glucocorticoid receptor. Endocrinology 114: 274-279
45. Nordeen SK 1987 Luciferase reporter gene vectors for analysis of promoters and enhancers. BioTechniques 6: 454-457
46. de Wet JR, Wood KV, Helinski DR, Subramani S 1987 Firefly luciferase gene: Structure and expression in mammalian cells. Mol Cell Biol 7: 725-737
47. Nordeen SK, Green PP, Fowlkes DM 1987 A rapid, sensitive, and inexpensive assay for chloramphenicol ace-tyltransferase. DNA 6: 173-178
48. Shepard AR, Eberhardt NL 1992 Thiols interfere with chloramphenicol acetyltransferase assays. BioTechniques 13: 702-704
49. Logeât F, Pamphile R, Loosfelt H, Jolivet A, Fournier A, Milgrom E 1985 One-step immunoaffinity purification of active progesterone receptor. Further evidence in favor of the existence of a single steroid binding subunit. Biochemistry 24: 1029-1035
50. Estes PA, Suba EJ, Lawler-Heavner J, Elashry-Stowers D, Wei LL, Toft DO, Sullivan WP, Horwitz KB, Edwards DP 1987 Immunologic analysis of human breast cancer progesterone receptors. 1. Immunoaffinity purification of transformed receptors and production of monoclonal antibodies. Biochemistry 26: 6250-6262
51. Lillie JW, Green MR 1989 Transcription activation by the adenovirus E1 a protein. Nature 338: 39-44
52. Gorman CM, Moffat LF, Howard BH 1982 Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol 2: 1044-1051